ArticleThe British journal of radiology2020
Deep learning based classification of solid lipid-poor contrast enhancing renal masses using contrast enhanced CT.
Article in The British journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Artificial intelligence in the radiologic diagnosis of major urological cancers: a meta-analysis.World journal of urology · 2026Pooled it
- Diagnostic performance of artificial intelligence in detection of renal cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Pooled it
- Parenchymatous invasive renal pelvis carcinoma in retrograde intrarenal surgery patients: a case report.BMC urology · 2026Article
- Machine learning based classification of aggressive and malignant renal tumors from multimodal data.PLOS digital health · 2026Article
- Deep Learning for Detecting and Subtyping Renal Cell Carcinoma on Contrast-Enhanced CT Scans Using 2D Neural Network with Feature Consistency Techniques.The Indian journal of radiology & imaging · 2025Article
- Computed Tomography-Based Radiomics Diagnostic Model for Fat-Poor Small Renal Tumor Subtypes.Diagnostics (Basel, Switzerland) · 2025Article
- Kidney Disease Segmentation and Classification Using Firefly Sigma Seeker and MagWeight Rank Techniques.Bioengineering (Basel, Switzerland) · 2025Article
- Review
- Convolutional neural networks for the differentiation between benign and malignant renal tumors with a multicenter international computed tomography dataset.Insights into imaging · 2024Article
- Application of artificial intelligence in the diagnosis and treatment of urinary tumors.Frontiers in oncology · 2024Review
- Creation of synthetic contrast-enhanced computed tomography images using deep neural networks to screen for renal cell carcinoma.Nagoya journal of medical science · 2023Article
- Artificial intelligence-based non-invasive tumor segmentation, grade stratification and prognosis prediction for clear-cell renal-cell carcinoma.Precision clinical medicine · 2023Article
- Recognizing pathology of renal tumor from macroscopic cross-section image by deep learning.Biomedical engineering online · 2023Article
- AI-Driven Robust Kidney and Renal Mass Segmentation and Classification on 3D CT Images.Bioengineering (Basel, Switzerland) · 2023Article
- Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature.Cancers · 2023Review
- Artificial intelligence for early detection of renal cancer in computed tomography: A review.Cambridge prisms. Precision medicine · 2023Review
- Deep learning techniques for imaging diagnosis of renal cell carcinoma: current and emerging trends.Frontiers in oncology · 2023Review
- Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review.European urology · 2022Review
- A Comprehensive Computer-Assisted Diagnosis System for Early Assessment of Renal Cancer Tumors.Sensors (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveEstablish a workflow that utilizes convolutional neural nets (CNN) to classify solid, lipid-poor, contrast enhancing renal masses using multiphase contrast enhanced CT (CECT) images and to assess the performance of the resulting network.
methodsIn this institutional review board approved study of 143 patients with predominantly solid, lipid-poor, contrast enhancing renal lesions (46 benign and 97 malignant), patients with a pre-operative multiphase CECT of the abdomen and pelvis obtained between June 2009 and June 2015 were retrospectively queried. Benign renal masses included oncocytoma and lipid-poor angiomyolipoma and the malignant group included clear cell, papillary, and chromophobe carcinomas.Region of interests of whole tumor volumes were manually segmented, and CT phase images with the largest cross-section of the segmented tumor in the axial plane were used for assessment. Post-surgical pathological evaluation was used to establish diagnosis.The segmented images of renal masses were used as input to a CNN. The data were augmented and split into training (83.9%) and validation sets (16.1%) to determine the hyperparameters of the CNN. Thereafter. the performance of the resulting CNN was quantified using eightfold cross-validation.
resultsThe CNN-based classifier demonstrated an overall accuracy of 78% (95% confidence interval: 76-80%), sensitivity of 70% (95% confidence interval: 66-74%), specificity of 81% (79-83%) and an area under the curve of 0.82.
conclusionA CNN-based classifier to diagnose solid enhancing malignant renal masses based on multiphase CECT images was developed. ADVANCES IN KNOWLEDGE: It was established that a CNN-based classifier could be trained to accurately distinguish malignant renal lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.